PFE - Pfizer Inc
A pharmaceutical heavyweight known for COVID-19 vaccines and treatments, now working to rebuild growth momentum through oncology acquisitions and pipeline diversification.
Finlify Score
52.3 / 100
Data Quality
PARTIAL
Penalty
-1.0
Sector
Health Care
Close Price
$26.00
-0.80%
52W Range
$23.11 - $28.75
Market Cap
$149.2B
-0.8%Compared to previous day
2026 Q1 Revenue
$12.1B
+133.1%Changes from last reporting quarter
2026 Q1 EPS
$0.00
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
52.2
40-70 moderate
2Y Range Position
48%
-17.6% from high / +24.3% from low
Beta
0.28
Relative to market benchmark
MACD
0.08
MACD line -0.08 / signal line -0.16
Fundamental Trend
Growth 73.8Financial Health
Quality 85.8Data Quality
PARTIALValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD52.3 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $12.1B+133.1% | -$36.5B-354.5% | $14.4B+16.0% | $12.4B+6.7% |
| Gross Profit | - | - | - | - |
| Operating Income | - | - | - | - |
| Net Income | $2.7B+263.0% | -$1.6B-146.5% | $3.5B+21.7% | $2.9B-1.9% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jun 16, 2026
Finlify's signal for PFE is HOLD, with a Finlify Score of 53.4 out of 100. This appears to be influenced by strong fundamental components somewhat offset by weaker technical indicators and partial data quality.
Technical
The asset's Relative Strength at 32.6/100 and Accumulation / Volume at 23.9/100 suggest a weaker technical posture. While the 20-day return shows a modest gain of 1.8%, the 60-day return indicates a decline of 4.1%, and the asset is 8.2% below its 52-week high. The RSI(14) of 53.7 appears to be in a neutral range.
Fundamentals
PFE demonstrates strong fundamental components, with a Fundamental Trend score of 73.8/100 and Financial Quality at 85.8/100. The asset's valuation metrics include a P/E of 19.2x, P/B of 1.6x, and P/S of 2.4x, which may appear reasonable. A Beta of 0.3 suggests lower volatility relative to the market, and the dividend yield stands at 6.57%. The Data Quality is noted as PARTIAL, with a deduction of -1.0 and an 'eps_proxy_used' flag, which suggests that data coverage may limit the completeness of the fundamental assessment.
Macro Context
The current macro environment, characterized by elevated CPI YoY at 4.3% and a 10Y Treasury Yield of 4.5%, could suggest a challenging backdrop for some sectors. However, a pharmaceutical company like PFE, with its defensive characteristics and a significant dividend yield, may exhibit some resilience in such an environment.
Key Risks
- Weaker technical momentum, as indicated by low Relative Strength (32.6/100) and Accumulation/Volume (23.9/100) scores.
- Partial data quality and the use of an EPS proxy, which may limit the completeness or accuracy of the fundamental assessment.
- Potential for sustained inflation (CPI YoY 4.3%) and higher interest rates (10Y Treasury 4.5%) to impact future earnings or discount rates.